Drug Patents owned by Scynexis

1. Drug name - BREXAFEMME

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US8188085 SCYNEXIS Antifungal agents
Aug, 2030

(7 years from now)

US10174074 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(12 years from now)

US10927142 SCYNEXIS Salts and polymorphs of SCY-078
Jan, 2035

(12 years from now)

CN102176827B SCYNEXIS Antifungal Preparation
Aug, 2029

(6 years from now)

CN102176827A SCYNEXIS Antifungal Agents
Aug, 2029

(6 years from now)

CN104877001B SCYNEXIS Antifungal Preparation
Aug, 2029

(6 years from now)

CN104877001A SCYNEXIS Anti-Fungal Formulation
Aug, 2029

(6 years from now)

IN201100410P2 SCYNEXIS Antifungal Agents
Aug, 2029

(6 years from now)

IN304757B SCYNEXIS Triazole-Substituted Derivatives Of Enfumafungin As Antifungal Agents
Aug, 2029

(6 years from now)

EP3247711B1 SCYNEXIS Novel Salts And Polymorphs Of Scy-078
Jan, 2036

(13 years from now)

EP3247711A1 SCYNEXIS Novel Salts And Polymorphs Of Scy-078
Jan, 2036

(13 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10370406 SCYNEXIS Salts and polymorphs of SCY-078 Jan, 2035

(12 years from now)

Drugs and Companies using IBREXAFUNGERP CITRATE ingredient

Treatment: Treatment of adult and post-menarchal pediatric females with vulvovaginal candidiasis (vvc)

Dosage: TABLET;ORAL

More Information on Dosage
Strength Dosage Availability
EQ 150MG BASE TABLET;ORAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.